Semi-mechanistic population pharmacokinetic model incorporating glutathione S-transferase activity for personalized busulfan dosing in pediatric allogeneic hematopoietic cell transplantation

结合谷胱甘肽S-转移酶活性的半机制群体药代动力学模型用于儿童异基因造血干细胞移植中布苏凡的个体化给药

阅读:5

Abstract

BACKGROUND: Busulfan is known for its high inter- and intra-individual pharmacokinetics/pharmacodynamics (PK/PD) variability, especially in children. Therefore, we aimed to identify factors affecting PK variability of busulfan in pediatric allogeneic hematopoietic cell transplantation (HCT) recipients and investigate the effect of glutathione S-transferase (GST) activity on busulfan metabolism using a semi-mechanistic population PK model. METHODS: Overall, 636 whole-blood busulfan concentrations from 65 pediatric HCT recipients were analyzed using nonlinear mixed-effects modeling. A semi-mechanistic population PK model was developed to describe busulfan metabolism in response to glutathione (GSH) depletion. The effects of potential covariates were selected based on previous study and physiologically-based theoretical mechanisms. Virtual clinical trials were conducted to compare different dosing strategies, and model-based optimal dosing regimen was recommended. RESULTS: A two-compartment model with first-order absorption was selected to describe busulfan PK. A GSH compartment was added to represent the relative amount of GSH available at any time. The estimated mean clearance of busulfan was 9.57 L h(-1) (relative standard error: 10.8%). Busulfan disposition was best described by including normal fat mass (NFM) allometrically and GST enzyme activity on S(GSH) exponentially. The S(GSH) increased by 40.6% as GST enzyme activity increased from 0.9 nmol/min/mL to 20.7 nmol/min/mL. Patients with weights (WT) of 9-16 kg are at high risk of sinusoidal obstructive syndrome (SOS) when receiving WT-based dosing strategy. CONCLUSION: NFM, age-dependent maturation function, and GST enzyme activity may contribute to busulfan PK variability. The WT-based dosing strategy showed a higher risk of SOS than the age-based dosing strategy in 9-16 kg patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。